Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Identifying and Targeting Nucleotide-Binding Oligomerization Domain-Containing 2 Pathway Biomarkers in Crohn’s Disease
FY 2024-25
Summary
Crohn disease (CD) is a chronic inflammatory disorder of the digestive system that affects millions of people worldwide. While the cause of CD is unknown, mutations in the NOD2 gene are strongly linked. NOD2 plays an important role in the gut immune system by detecting a bacterial compound called muramyl-dipeptide (MDP) and triggering an immune response. People with defective NOD2 genes are many times more likely to develop CD, but the reason for this increased risk is not fully understood. Certain beneficial bacteria in the gut produce MDP through enzymes called peptidoglycan (PGN) hydrolases, potentially maintaining a healthy gut immune response by activating NOD2. Our research will explore how MDP and PGN-hydrolases are linked to CD onset and whether increasing MDP levels could help prevent or treat CD.Stool samples from at risk individuals will be analyzed for levels of MDP and abundances of PGN-hydrolases. By correlating MDP levels and PGN-hydrolases abundances, we can identify which enzymes or bacteria are producing the most MDP or are most associated with high MDP levels. Using well-studied PGN-hydrolases and previously identified enzymes of interest, we plan to engineer safe probiotic strains that can increase MDP levels. Successful strains will be screened and then tested individually or in combination with mice to see if they improve NOD2 activation and reduce gut inflammation. This research may reveal an important contributor to CD development and a preclinical, minimally invasive marker of CD risk. Additionally, there is the potential to introduce new therapeutic strategies for CD through regulating the NOD2 pathway.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529855
Name
Ren Mu Yan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying and Targeting Nucleotide-Binding Oligomerization Domain-Containing 2 Pathway Biomarkers in Crohn’s Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crohn’S Disease; Dl-Endopeptidase; Gut Microbiota; Metagenomics; Nod2; Peptidoglycan
Abstract
Crohn disease (CD) is a chronic inflammatory disorder of the digestive system that affects millions of people worldwide. While the cause of CD is unknown, mutations in the NOD2 gene are strongly linked. NOD2 plays an important role in the gut immune system by detecting a bacterial compound called muramyl-dipeptide (MDP) and triggering an immune response. People with defective NOD2 genes are many times more likely to develop CD, but the reason for this increased risk is not fully understood. Certain beneficial bacteria in the gut produce MDP through enzymes called peptidoglycan (PGN) hydrolases, potentially maintaining a healthy gut immune response by activating NOD2. Our research will explore how MDP and PGN-hydrolases are linked to CD onset and whether increasing MDP levels could help prevent or treat CD.Stool samples from at risk individuals will be analyzed for levels of MDP and abundances of PGN-hydrolases. By correlating MDP levels and PGN-hydrolases abundances, we can identify which enzymes or bacteria are producing the most MDP or are most associated with high MDP levels. Using well-studied PGN-hydrolases and previously identified enzymes of interest, we plan to engineer safe probiotic strains that can increase MDP levels. Successful strains will be screened and then tested individually or in combination with mice to see if they improve NOD2 activation and reduce gut inflammation. This research may reveal an important contributor to CD development and a preclinical, minimally invasive marker of CD risk. Additionally, there is the potential to introduce new therapeutic strategies for CD through regulating the NOD2 pathway.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ren, Mu Yan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~